Display options
Cite
Dareng EO, Tyrer JP, Barnes DR, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022;doi: 10.1038/s41431-021-00987-7.
Dareng, E. O., Tyrer, J. P., Barnes, D. R., Jones, M. R., Yang, X., Aben, K. K. H., Adank, M. A., Agata, S., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Aravantinos, G., Arun, B. K., Augustinsson, A., Balmaña, J., Bandera, E. V., Barkardottir, R. B., Barrowdale, D., Beckmann, M. W., Beeghly-Fadiel, A., Benitez, J., Bermisheva, M., Bernardini, M. Q., Bjorge, L., Black, A., Bogdanova, N. V., Bonanni, B., Borg, A., Brenton, J. D., Budzilowska, A., Butzow, R., Buys, S. S., Cai, H., Caligo, M. A., Campbell, I., Cannioto, R., Cassingham, H., Chang-Claude, J., Chanock, S. J., Chen, K., Chiew, Y. E., Chung, W. K., Claes, K. B. M., Colonna, S., Cook, L. S., Couch, F. J., Daly, M. B., Dao, F., Davies, E., de la Hoya, M., de Putter, R., Dennis, J., DePersia, A., Devilee, P., Diez, O., Ding, Y. C., Doherty, J. A., Domchek, S. M., Dörk, T., du Bois, A., Dürst, M., Eccles, D. M., Eliassen, H. A., Engel, C., Evans, G. D., Fasching, P. A., Flanagan, J. M., Fortner, R. T., Machackova, E., Friedman, E., Ganz, P. A., Garber, J., Gensini, F., Giles, G. G., Glendon, G., Godwin, A. K., Goodman, M. T., Greene, M. H., Gronwald, J., Hahnen, E., Haiman, C. A., Håkansson, N., Hamann, U., Hansen, T. V. O., Harris, H. R., Hartman, M., Heitz, F., Hildebrandt, M. A. T., Høgdall, E., Høgdall, C. K., Hopper, J. L., Huang, R. Y., Huff, C., Hulick, P. J., Huntsman, D. G., Imyanitov, E. N., Isaacs, C., Jakubowska, A., James, P. A., Janavicius, R., Jensen, A., Johannsson, O. T., John, E. M., Jones, M. E., Kang, D., Karlan, B. Y., Karnezis, A., Kelemen, L. E., Khusnutdinova, E., Kiemeney, L. A., Kim, B. G., Kjaer, S. K., Komenaka, I., Kupryjanczyk, J., Kurian, A. W., Kwong, A., Lambrechts, D., Larson, M. C., Lazaro, C., Le, N. D., Leslie, G., Lester, J., Lesueur, F., Levine, D. A., Li, L., Li, J., Loud, J. T., Lu, K. H., Lubiński, J., Mai, P. L., Manoukian, S., Marks, J. R., Matsuno, R. K., Matsuo, K., May, T., McGuffog, L., McLaughlin, J. R., McNeish, I. A., Mebirouk, N., Menon, U., Miller, A., Milne, R. L., Minlikeeva, A., Modugno, F., Montagna, M., Moysich, K. B., Munro, E., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H., Yie, J. N. Y., Nielsen, H. R., Nielsen, F. C., Nikitina-Zake, L., Odunsi, K., Offit, K., Olah, E., Olbrecht, S., Olopade, O. I., Olson, S. H., Olsson, H., Osorio, A., Papi, L., Park, S. K., Parsons, M. T., Pathak, H., Pedersen, I. S., Peixoto, A., Pejovic, T., Perez-Segura, P., Permuth, J. B., Peshkin, B., Peterlongo, P., Piskorz, A., Prokofyeva, D., Radice, P., Rantala, J., Riggan, M. J., Risch, H. A., Rodriguez-Antona, C., Ross, E., Rossing, M. A., Runnebaum, I., Sandler, D. P., Santamariña, M., Soucy, P., Schmutzler, R. K., Setiawan, V. W., Shan, K., Sieh, W., Simard, J., Singer, C. F., Sokolenko, A. P., Song, H., Southey, M. C., Steed, H., Stoppa-Lyonnet, D., Sutphen, R., Swerdlow, A. J., Tan, Y. Y., Teixeira, M. R., Teo, S. H., Terry, K. L., Terry, M. B., Thomassen, M., Thompson, P. J., Thomsen, L. C. V., Thull, D. L., Tischkowitz, M., Titus, L., Toland, A. E., Torres, D., Trabert, B., Travis, R., Tung, N., Tworoger, S. S., Valen, E., van Altena, A. M., van der Hout, A. H., Van Nieuwenhuysen, E., van Rensburg, E. J., Vega, A., Edwards, D. V., Vierkant, R. A., Wang, F., Wappenschmidt, B., Webb, P. M., Weinberg, C. R., Weitzel, J. N., Wentzensen, N., White, E., Whittemore, A. S., Winham, S. J., Wolk, A., Woo, Y. L., Wu, A. H., Yan, L., Yannoukakos, D., Zavaglia, K. M., Zheng, W., Ziogas, A., Zorn, K. K., Kleibl, Z., Easton, D., Lawrenson, K., DeFazio, A., Sellers, T. A., Ramus, S. J., Pearce, C. L., Monteiro, A. N., Cunningham, J., Goode, E. L., Schildkraut, J. M., Berchuck, A., Chenevix-Trench, G., Gayther, S. A., Antoniou, A. C., & Pharoah, P. D. P. (2022). Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European journal of human genetics : EJHG, . https://doi.org/10.1038/s41431-021-00987-7
Dareng, Eileen O, et al. "Polygenic risk modeling for prediction of epithelial ovarian cancer risk." European journal of human genetics : EJHG vol. (2022). doi: https://doi.org/10.1038/s41431-021-00987-7
Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 Jan 14; doi: 10.1038/s41431-021-00987-7. Epub 2022 Jan 14. PMID: 35027648.
Copy Download .nbib Format: NLM
Share it on

Eur J Hum Genet. 2022 Jan 14; doi: 10.1038/s41431-021-00987-7. Epub 2022 Jan 14.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

European journal of human genetics : EJHG

Eileen O Dareng, Jonathan P Tyrer, Daniel R Barnes, Michelle R Jones, Xin Yang, Katja K H Aben, Muriel A Adank, Simona Agata, Irene L Andrulis, Hoda Anton-Culver, Natalia N Antonenkova, Gerasimos Aravantinos, Banu K Arun, Annelie Augustinsson, Judith Balmaña, Elisa V Bandera, Rosa B Barkardottir, Daniel Barrowdale, Matthias W Beckmann, Alicia Beeghly-Fadiel, Javier Benitez, Marina Bermisheva, Marcus Q Bernardini, Line Bjorge, Amanda Black, Natalia V Bogdanova, Bernardo Bonanni, Ake Borg, James D Brenton, Agnieszka Budzilowska, Ralf Butzow, Saundra S Buys, Hui Cai, Maria A Caligo, Ian Campbell, Rikki Cannioto, Hayley Cassingham, Jenny Chang-Claude, Stephen J Chanock, Kexin Chen, Yoke-Eng Chiew, Wendy K Chung, Kathleen B M Claes, Sarah Colonna, Linda S Cook, Fergus J Couch, Mary B Daly, Fanny Dao, Eleanor Davies, Miguel de la Hoya, Robin de Putter, Joe Dennis, Allison DePersia, Peter Devilee, Orland Diez, Yuan Chun Ding, Jennifer A Doherty, Susan M Domchek, Thilo Dörk, Andreas du Bois, Matthias Dürst, Diana M Eccles, Heather A Eliassen, Christoph Engel, Gareth D Evans, Peter A Fasching, James M Flanagan, Renée T Fortner, Eva Machackova, Eitan Friedman, Patricia A Ganz, Judy Garber, Francesca Gensini, Graham G Giles, Gord Glendon, Andrew K Godwin, Marc T Goodman, Mark H Greene, Jacek Gronwald, Eric Hahnen, Christopher A Haiman, Niclas Håkansson, Ute Hamann, Thomas V O Hansen, Holly R Harris, Mikael Hartman, Florian Heitz, Michelle A T Hildebrandt, Estrid Høgdall, Claus K Høgdall, John L Hopper, Ruea-Yea Huang, Chad Huff, Peter J Hulick, David G Huntsman, Evgeny N Imyanitov, Claudine Isaacs, Anna Jakubowska, Paul A James, Ramunas Janavicius, Allan Jensen, Oskar Th Johannsson, Esther M John, Michael E Jones, Daehee Kang, Beth Y Karlan, Anthony Karnezis, Linda E Kelemen, Elza Khusnutdinova, Lambertus A Kiemeney, Byoung-Gie Kim, Susanne K Kjaer, Ian Komenaka, Jolanta Kupryjanczyk, Allison W Kurian, Ava Kwong, Diether Lambrechts, Melissa C Larson, Conxi Lazaro, Nhu D Le, Goska Leslie, Jenny Lester, Fabienne Lesueur, Douglas A Levine, Lian Li, Jingmei Li, Jennifer T Loud, Karen H Lu, Jan Lubiński, Phuong L Mai, Siranoush Manoukian, Jeffrey R Marks, Rayna Kim Matsuno, Keitaro Matsuo, Taymaa May, Lesley McGuffog, John R McLaughlin, Iain A McNeish, Noura Mebirouk, Usha Menon, Austin Miller, Roger L Milne, Albina Minlikeeva, Francesmary Modugno, Marco Montagna, Kirsten B Moysich, Elizabeth Munro, Katherine L Nathanson, Susan L Neuhausen, Heli Nevanlinna, Joanne Ngeow Yuen Yie, Henriette Roed Nielsen, Finn C Nielsen, Liene Nikitina-Zake, Kunle Odunsi, Kenneth Offit, Edith Olah, Siel Olbrecht, Olufunmilayo I Olopade, Sara H Olson, Håkan Olsson, Ana Osorio, Laura Papi, Sue K Park, Michael T Parsons, Harsha Pathak, Inge Sokilde Pedersen, Ana Peixoto, Tanja Pejovic, Pedro Perez-Segura, Jennifer B Permuth, Beth Peshkin, Paolo Peterlongo, Anna Piskorz, Darya Prokofyeva, Paolo Radice, Johanna Rantala, Marjorie J Riggan, Harvey A Risch, Cristina Rodriguez-Antona, Eric Ross, Mary Anne Rossing, Ingo Runnebaum, Dale P Sandler, Marta Santamariña, Penny Soucy, Rita K Schmutzler, V Wendy Setiawan, Kang Shan, Weiva Sieh, Jacques Simard, Christian F Singer, Anna P Sokolenko, Honglin Song, Melissa C Southey, Helen Steed, Dominique Stoppa-Lyonnet, Rebecca Sutphen, Anthony J Swerdlow, Yen Yen Tan, Manuel R Teixeira, Soo Hwang Teo, Kathryn L Terry, Mary Beth Terry, Mads Thomassen, Pamela J Thompson, Liv Cecilie Vestrheim Thomsen, Darcy L Thull, Marc Tischkowitz, Linda Titus, Amanda E Toland, Diana Torres, Britton Trabert, Ruth Travis, Nadine Tung, Shelley S Tworoger, Ellen Valen, Anne M van Altena, Annemieke H van der Hout, Els Van Nieuwenhuysen, Elizabeth J van Rensburg, Ana Vega, Digna Velez Edwards, Robert A Vierkant, Frances Wang, Barbara Wappenschmidt, Penelope M Webb, Clarice R Weinberg, Jeffrey N Weitzel, Nicolas Wentzensen, Emily White, Alice S Whittemore, Stacey J Winham, Alicja Wolk, Yin-Ling Woo, Anna H Wu, Li Yan, Drakoulis Yannoukakos, Katia M Zavaglia, Wei Zheng, Argyrios Ziogas, Kristin K Zorn, Zdenek Kleibl, Douglas Easton, Kate Lawrenson, Anna DeFazio, Thomas A Sellers, Susan J Ramus, Celeste L Pearce, Alvaro N Monteiro, Julie Cunningham, Ellen L Goode, Joellen M Schildkraut, Andrew Berchuck, Georgia Chenevix-Trench, Simon A Gayther, Antonis C Antoniou, Paul D P Pharoah

Affiliations

  1. University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
  2. University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK.
  3. Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  4. Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  5. Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  6. The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands.
  7. Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy.
  8. Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada.
  9. University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada.
  10. University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA.
  11. N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  12. 'Agii Anargiri' Cancer Hospital, Athens, Greece.
  13. University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX, USA.
  14. Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden.
  15. Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain.
  16. University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain.
  17. Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New Brunswick, NJ, USA.
  18. Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland.
  19. University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland.
  20. University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany.
  21. Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  22. Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
  23. Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain.
  24. Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia.
  25. Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada.
  26. Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway.
  27. University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway.
  28. National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.
  29. Hannover Medical School, Department of Radiation Oncology, Hannover, Germany.
  30. Hannover Medical School, Gynaecology Research Unit, Hannover, Germany.
  31. IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, Italy.
  32. Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden.
  33. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  34. Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland.
  35. University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki, Finland.
  36. Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA.
  37. University Hospital, SOD Genetica Molecolare, Pisa, Italy.
  38. Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
  39. The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.
  40. Roswell Park Cancer Institute, Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Buffalo, NY, USA.
  41. Division of Human Genetics, The Ohio State University, Department of Internal Medicine, Columbus, OH, USA.
  42. German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
  43. University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany.
  44. National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.
  45. Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China.
  46. The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
  47. Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia.
  48. Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA.
  49. Ghent University, Centre for Medical Genetics, Gent, Belgium.
  50. University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  51. Alberta Health Services, Department of Cancer Epidemiology and Prevention Research, Calgary, AB, Canada.
  52. Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
  53. Fox Chase Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA.
  54. Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, New York, NY, USA.
  55. Cambridge, Cambridge, UK.
  56. CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Molecular Oncology Laboratory, Madrid, Spain.
  57. NorthShore University Health System, Center for Medical Genetics, Evanston, IL, USA.
  58. The University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
  59. Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands.
  60. Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands.
  61. Vall dHebron Institute of Oncology (VHIO), Oncogenetics Group, Barcelona, Spain.
  62. University Hospital Vall dHebron, Clinical and Molecular Genetics Area, Barcelona, Spain.
  63. Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, CA, USA.
  64. University of Utah, Huntsman Cancer Institute, Department of Population Health Sciences, Salt Lake City, UT, USA.
  65. University of Pennsylvania, Basser Center for BRCA, Abramson Cancer Center, Philadelphia, PA, USA.
  66. Ev. Kliniken Essen-Mitte (KEM), Department of Gynecology and Gynecologic Oncology, Essen, Germany.
  67. Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany.
  68. Jena University Hospital-Friedrich Schiller University, Department of Gynaecology, Jena, Germany.
  69. University of Southampton, Faculty of Medicine, Southampton, UK.
  70. Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA.
  71. Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA, USA.
  72. University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany.
  73. University of Leipzig, LIFE-Leipzig Research Centre for Civilization Diseases, Leipzig, Germany.
  74. University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK.
  75. St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, UK.
  76. University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA.
  77. Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, London, UK.
  78. Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics, Brno, Czech Republic.
  79. Chaim Sheba Medical Center, The Susanne Levy Gertner Oncogenetics Unit, Ramat Gan, Israel.
  80. Tel Aviv University, Sackler Faculty of Medicine, Ramat Aviv, Israel.
  81. Jonsson Comprehensive Cancer Centre, UCLA, Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Los Angeles, CA, USA.
  82. Dana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA, USA.
  83. University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, Florence, Italy.
  84. Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, VIC, Australia.
  85. The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, VIC, Australia.
  86. Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC, Australia.
  87. University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, USA.
  88. Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, CA, USA.
  89. National Cancer Institute, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.
  90. Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland.
  91. Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Familial Breast and Ovarian Cancer, Cologne, Germany.
  92. Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany.
  93. University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA.
  94. Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden.
  95. German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany.
  96. Rigshospitalet, Copenhagen University Hospital, Department of Clinical Genetics, Copenhagen, Denmark.
  97. Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, WA, USA.
  98. University of Washington, Department of Epidemiology, Seattle, WA, USA.
  99. National University of Singapore and National University Health System, Saw Swee Hock School of Public Health, Singapore, Singapore.
  100. National University Health System, Department of Surgery, Singapore, Singapore.
  101. Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Berlin, Germany.
  102. University of Texas MD Anderson Cancer Center, Department of Epidemiology, Houston, TX, USA.
  103. Danish Cancer Society Research Center, Department of Virus, Lifestyle and Genes, Copenhagen, Denmark.
  104. University of Copenhagen, Molecular Unit, Department of Pathology, Herlev Hospital, Copenhagen, Denmark.
  105. University of Copenhagen, Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark.
  106. Roswell Park Cancer Institute, Center For Immunotherapy, Buffalo, NY, USA.
  107. BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver, BC, Canada.
  108. University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada.
  109. University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, BC, Canada.
  110. BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, BC, Canada.
  111. N.N. Petrov Institute of Oncology, St. Petersburg, Russia.
  112. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
  113. Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic Diagnostics, Szczecin, Poland.
  114. Peter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, VIC, Australia.
  115. Vilnius University Hospital Santariskiu Clinics, Hematology, oncology and transfusion medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius, Lithuania.
  116. State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
  117. Landspitali University Hospital, Department of Oncology, Reykjavik, Iceland.
  118. Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, USA.
  119. Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA.
  120. The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK.
  121. Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, Korea.
  122. Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea.
  123. Seoul National University, Cancer Research Institute, Seoul, Korea.
  124. University of California at Los Angeles, David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA.
  125. UC Davis Medical Center, Department of Pathology and Laboratory Medicine, Sacramento, CA, USA.
  126. Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA.
  127. Saint Petersburg State University, Saint Petersburg, Russia.
  128. Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea.
  129. City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA.
  130. Cancer Genetics Centre, Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong.
  131. The University of Hong Kong, Department of Surgery, Pok Fu Lam, Hong Kong.
  132. Hong Kong Sanatorium and Hospital, Department of Surgery, Happy Valley, Hong Kong.
  133. VIB Center for Cancer Biology, Leuven, Belgium.
  134. University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium.
  135. Mayo Clinic, Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Rochester, MN, USA.
  136. ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Hereditary Cancer Program, Barcelona, Spain.
  137. BC Cancer, Cancer Control Research, Vancouver, BC, Canada.
  138. Institut Curie, Paris, France.
  139. Mines ParisTech, Fontainebleau, France.
  140. Inserm U900, Genetic Epidemiology of Cancer team, Paris, France.
  141. NYU Langone Medical Center, Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, New York, NY, USA.
  142. Genome Institute of Singapore, Human Genetics Division, Singapore, Singapore.
  143. University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Clinical Cancer Genetics Program, Houston, TX, USA.
  144. Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  145. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Unit of Medical Genetics, Department of Medical Oncology and Hematology, Milan, Italy.
  146. Duke University Hospital, Department of Surgery, Durham, NC, USA.
  147. University of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, HI, USA.
  148. Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, Nagoya, Japan.
  149. Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, Japan.
  150. Samuel Lunenfeld Research Institute, Public Health Ontario, Toronto, ON, Canada.
  151. Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, UK.
  152. University of Glasgow, Institute of Cancer Sciences, Glasgow, UK.
  153. University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
  154. Roswell Park Cancer Institute, NRG Oncology, Statistics and Data Management Center, Buffalo, NY, USA.
  155. Roswell Park Cancer Institute, Division of Cancer Prevention and Control, Buffalo, NY, USA.
  156. Magee-Womens Research Institute and Hillman Cancer Center, Womens Cancer Research Center, Pittsburgh, PA, USA.
  157. University of Pittsburgh School of Medicine, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA, USA.
  158. Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA.
  159. Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
  160. University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.
  161. National Cancer Centre, Cancer Genetics Service, Singapore, Singapore.
  162. Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore.
  163. Odense University Hospital, Department of Clinical Genetics, Odence C, Denmark.
  164. Latvian Biomedical Research and Study Centre, Riga, Latvia.
  165. Roswell Park Cancer Institute, Department of Gynecologic Oncology, Buffalo, NY, USA.
  166. Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, New York, NY, USA.
  167. Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, New York, NY, USA.
  168. National Institute of Oncology, Department of Molecular Genetics, Budapest, Hungary.
  169. University Hospitals Leuven, Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, Leuven, Belgium.
  170. The University of Chicago, Center for Clinical Cancer Genetics, Chicago, IL, USA.
  171. Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
  172. Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  173. QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD, Australia.
  174. Aalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark.
  175. Aalborg University Hospital, Clinical Cancer Research Center, Aalborg, Denmark.
  176. Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.
  177. Portuguese Oncology Institute, Department of Genetics, Porto, Portugal.
  178. Moffitt Cancer Center, Department of Cancer Epidemiology, Tampa, FL, USA.
  179. IFOM-the FIRC Institute of Molecular Oncology, Genome Diagnostics Program, Milan, Italy.
  180. Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa, Russia.
  181. Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, Italy.
  182. Karolinska Institutet, Clinical Genetics, Stockholm, Sweden.
  183. Duke University Hospital, Department of Gynecologic Oncology, Durham, NC, USA.
  184. Yale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, USA.
  185. Fox Chase Cancer Center, Population Studies Facility, Philadelphia, PA, USA.
  186. National Institute of Environmental Health Sciences, NIH, Epidemiology Branch, Research Triangle Park, NC, USA.
  187. Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain.
  188. Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain.
  189. Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Genomics Center, Québec City, QC, Canada.
  190. Faculty of Medicine and University Hospital Cologne, University of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
  191. Hebei Medical University, Fourth Hospital, Department of Obstetrics and Gynaecology, Shijiazhuang, China.
  192. Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, New York, NY, USA.
  193. Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, NY, USA.
  194. Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Genomic Center, Québec City, QC, Canada.
  195. Medical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria.
  196. University of Cambridge, Department of Public Health and Primary Care, Cambridge, UK.
  197. The University of Melbourne, Department of Clinical Pathology, Melbourne, VIC, Australia.
  198. Royal Alexandra Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Edmonton, AB, Canada.
  199. INSERM U830, Department of Tumour Biology, Paris, France.
  200. Institut Curie, Service de Génétique, Paris, France.
  201. Université Paris Descartes, Paris, France.
  202. University of South Florida, Epidemiology Center, College of Medicine, Tampa, FL, USA.
  203. The Institute of Cancer Research, Division of Breast Cancer Research, London, UK.
  204. University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal.
  205. Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, Malaysia.
  206. University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, Malaysia.
  207. Brigham and Women's Hospital and Harvard Medical School, Obstetrics and Gynecology Epidemiology Center, Boston, MA, USA.
  208. Columbia University, Department of Epidemiology, Mailman School of Public Health, New York, NY, USA.
  209. Magee-Womens Hospital, University of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh, PA, USA.
  210. McGill University, Program in Cancer Genetics, Departments of Human Genetics and Oncology, Montréal, QC, Canada.
  211. University of Cambridge, Department of Medical Genetics, Cambridge, UK.
  212. Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
  213. The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH, USA.
  214. Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, Colombia.
  215. University of Oxford, Cancer Epidemiology Unit, Oxford, UK.
  216. Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA, USA.
  217. University Medical Center Groningen, University Groningen, Department of Genetics, Groningen, The Netherlands.
  218. University of Pretoria, Department of Genetics, Arcadia, South Africa.
  219. Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
  220. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  221. Vanderbilt University Medical Center, Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Nashville, TN, USA.
  222. Duke Cancer Institute, Cancer Control and Population Sciences, Durham, NC, USA.
  223. Duke University Hospital, Department of Community and Family Medicine, Durham, NC, USA.
  224. QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, QLD, Australia.
  225. National Institute of Environmental Health Sciences, NIH, Biostatistics and Computational Biology Branch, Research Triangle Park, NC, USA.
  226. City of Hope, Clinical Cancer Genomics, Duarte, CA, USA.
  227. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  228. Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA.
  229. Uppsala University, Department of Surgical Sciences, Uppsala, Sweden.
  230. University of Malaya, Department of Obstetrics and Gynaecology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
  231. Hebei Medical University, Fourth Hospital, Department of Molecular Biology, Shijiazhuang, China.
  232. National Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory, INRASTES, Athens, Greece.
  233. Institute of Biochemistry and Experimental Oncology, First Faculty od Medicine, Charles University, Prague, Czech Republic.
  234. Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Centre, Department of Obstetrics and Gynecology, Los Angeles, CA, USA.
  235. Royal Pass Road, Tampa, FL, USA.
  236. University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, NSW, Australia.
  237. University of NSW Sydney, Adult Cancer Program, Lowy Cancer Research Centre, Sydney, NSW, Australia.
  238. University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI, USA.
  239. University of Southern California Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA.
  240. Mayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, MN, USA.
  241. Emory University, Department of Epidemiology, Rollins School of Public Health, Atlanta, GA, USA.
  242. University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK. [email protected].
  243. University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK. [email protected].

PMID: 35027648 DOI: 10.1038/s41431-021-00987-7

Abstract

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

© 2021. The Author(s).

References

  1. Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147:705–13. - PubMed
  2. Lyra PCM, Rangel LB, Monteiro ANA. Functional landscape of common variants associated with susceptibility to epithelial ovarian cancer. Curr Epidemiol Rep. 2020;7:49–57. - PubMed
  3. Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, et al. Common genetic variation and susceptibility to ovarian cancer: current insights and future directions. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2018;27:395–404. - PubMed
  4. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007;17:1520–8. - PubMed
  5. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, International Schizophrenia Consortium. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52. - PubMed
  6. Abraham G, Kowalczyk A, Zobel J, Inouye M. Performance and robustness of penalized and unpenalized methods for genetic prediction of complex human disease. Genet Epidemiol. 2013;37:184–95. - PubMed
  7. Habier D, Fernando RL, Kizilkaya K, Garrick DJ. Extension of the bayesian alphabet for genomic selection. BMC Bioinformatics. 2011;12:186. - PubMed
  8. Szymczak S, Biernacka JM, Cordell HJ, González-Recio O, König IR, Zhang H, et al. Machine learning in genome-wide association studies. Genet Epidemiol. 2009;33:S51–57. - PubMed
  9. Privé F, Aschard H, Blum MGB. Efficient implementation of penalized regression for genetic risk prediction. Genetics. 2019;212:65–74. - PubMed
  10. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized regression on summary statistics. Genet Epidemiol. 2017;41:469–80. - PubMed
  11. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:i53–7. - PubMed
  12. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49:680–91. - PubMed
  13. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–9. - PubMed
  14. Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, et al. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol. 2019;153:343–55. - PubMed
  15. Manichaikul A, Peres LC, Wang X-Q, Barnard ME, Chyn D, Sheng X, et al. Identification of novel epithelial ovarian cancer loci in women of African ancestry. Int J Cancer. 2020;146:2987–98. - PubMed
  16. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49:680–91. - PubMed
  17. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44:369–75. S1-3 - PubMed
  18. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. Am J Hum Genet. 2015;97:576–92. - PubMed
  19. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776. - PubMed
  20. Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med Off J Am Coll Med Genet. 2020;15:576–92. - PubMed
  21. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402–16. - PubMed
  22. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21–34. - PubMed
  23. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928–36. - PubMed
  24. Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109. - PubMed
  25. Yang X, Leslie G, Gentry-Maharaj A, Ryan A, Intermaggio M, Lee A, et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J Med Genet. 2018;55:546–54. - PubMed
  26. Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, et al. Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers. JNCI Cancer Spectr. 2020;4:pkaa021. - PubMed
  27. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2021;58:305–13. - PubMed
  28. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:674–85. - PubMed
  29. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med Off J Am Coll Med Genet. 2019;21:1708–18. - PubMed
  30. Welcome to CanRisk. [cited 2021 Aug 15]. https://canrisk.org/ - PubMed
  31. Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017;13:e1005589. - PubMed
  32. Gola D, Erdmann J, Müller-Myhsok B, Schunkert H, König IR. Polygenic risk scores outperform machine learning methods in predicting coronary artery disease status. Genet Epidemiol. 2020;44:125–38. - PubMed
  33. Paré G, Mao S, Deng WQ. A machine-learning heuristic to improve gene score prediction of polygenic traits. Sci Rep. 2017;7:12665. - PubMed

Publication Types